Toxin-Based Targeted Therapy for Malignant Brain Tumors
Despite advances in conventional treatment modalities for malignant brain tumors—surgery, radiotherapy, and chemotherapy—the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel the...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2012/480429 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850212973043253248 |
|---|---|
| author | Vidyalakshmi Chandramohan John H. Sampson Ira Pastan Darell D. Bigner |
| author_facet | Vidyalakshmi Chandramohan John H. Sampson Ira Pastan Darell D. Bigner |
| author_sort | Vidyalakshmi Chandramohan |
| collection | DOAJ |
| description | Despite advances in conventional treatment modalities for malignant brain tumors—surgery, radiotherapy, and chemotherapy—the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel therapies. Advances in genomic and proteomic research indicate that treatment of brain tumor patients can be increasingly personalized according to the characteristics of the targeted tumor and its environment. Consequently, during the last two decades, a novel class of investigative drug candidates for the treatment of central nervous system neoplasia has emerged: recombinant fusion protein conjugates armed with cytotoxic agents targeting tumor-specific antigens. The clinical applicability of the tumor-antigen-directed cytotoxic proteins as a safe and viable therapy for brain tumors is being investigated. Thus far, results from ongoing clinical trials are encouraging, as disease stabilization and patient survival prolongation have been observed in at least 109 cases. This paper summarizes the major findings pertaining to treatment with the different antiglioma cytotoxins at the preclinical and clinical stages. |
| format | Article |
| id | doaj-art-8c33b83c24f74f2da648d60f248fbd48 |
| institution | OA Journals |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-8c33b83c24f74f2da648d60f248fbd482025-08-20T02:09:13ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/480429480429Toxin-Based Targeted Therapy for Malignant Brain TumorsVidyalakshmi Chandramohan0John H. Sampson1Ira Pastan2Darell D. Bigner3Department of Pathology, Duke University Medical Center, Durham, NC 27710, USADepartment of Surgery, Duke University Medical Center, Durham, NC 27710, USALaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USADepartment of Pathology, Duke University Medical Center, Durham, NC 27710, USADespite advances in conventional treatment modalities for malignant brain tumors—surgery, radiotherapy, and chemotherapy—the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel therapies. Advances in genomic and proteomic research indicate that treatment of brain tumor patients can be increasingly personalized according to the characteristics of the targeted tumor and its environment. Consequently, during the last two decades, a novel class of investigative drug candidates for the treatment of central nervous system neoplasia has emerged: recombinant fusion protein conjugates armed with cytotoxic agents targeting tumor-specific antigens. The clinical applicability of the tumor-antigen-directed cytotoxic proteins as a safe and viable therapy for brain tumors is being investigated. Thus far, results from ongoing clinical trials are encouraging, as disease stabilization and patient survival prolongation have been observed in at least 109 cases. This paper summarizes the major findings pertaining to treatment with the different antiglioma cytotoxins at the preclinical and clinical stages.http://dx.doi.org/10.1155/2012/480429 |
| spellingShingle | Vidyalakshmi Chandramohan John H. Sampson Ira Pastan Darell D. Bigner Toxin-Based Targeted Therapy for Malignant Brain Tumors Clinical and Developmental Immunology |
| title | Toxin-Based Targeted Therapy for Malignant Brain Tumors |
| title_full | Toxin-Based Targeted Therapy for Malignant Brain Tumors |
| title_fullStr | Toxin-Based Targeted Therapy for Malignant Brain Tumors |
| title_full_unstemmed | Toxin-Based Targeted Therapy for Malignant Brain Tumors |
| title_short | Toxin-Based Targeted Therapy for Malignant Brain Tumors |
| title_sort | toxin based targeted therapy for malignant brain tumors |
| url | http://dx.doi.org/10.1155/2012/480429 |
| work_keys_str_mv | AT vidyalakshmichandramohan toxinbasedtargetedtherapyformalignantbraintumors AT johnhsampson toxinbasedtargetedtherapyformalignantbraintumors AT irapastan toxinbasedtargetedtherapyformalignantbraintumors AT darelldbigner toxinbasedtargetedtherapyformalignantbraintumors |